| Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis JD Wallach, AC Egilman, SS Dhruva, ME McCarthy, JE Miller, S Woloshin, ... bmj 361, 2018 | 67 | 2018 |
| Trends in prescription drug launch prices, 2008-2021 BN Rome, AC Egilman, AS Kesselheim JAMA 327 (21), 2145-2147, 2022 | 57 | 2022 |
| Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease JD Wallach, S Serghiou, L Chu, AC Egilman, V Vasiliou, JS Ross, ... BMC medical research methodology 20, 1-10, 2020 | 39 | 2020 |
| Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022 BN Rome, S Nagar, AC Egilman, J Wang, WB Feldman, AS Kesselheim JAMA Health Forum 4 (1), e225218-e225218, 2023 | 29 | 2023 |
| Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration J Puthumana, AC Egilman, AD Zhang, JL Schwartz, JS Ross JAMA Internal Medicine 181 (4), 559-560, 2021 | 29 | 2021 |
| Transparency of regulatory data across the European medicines agency, health Canada, and US food and Drug Administration AC Egilman, A Kapczynski, ME McCarthy, AT Luxkaranayagam, ... Journal of Law, Medicine & Ethics 49 (3), 456-485, 2021 | 26 | 2021 |
| Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences JD Wallach, AC Egilman, AD Gopal, N Swami, HM Krumholz, JS Ross Research integrity and peer review 3, 1-8, 2018 | 25 | 2018 |
| Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk L Chu, JPA Ioannidis, AC Egilman, V Vasiliou, JS Ross, JD Wallach International journal of epidemiology 49 (2), 608-618, 2020 | 21 | 2020 |
| Timeliness of postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis JD Wallach, AC Egilman, JS Ross, S Woloshin, LM Schwartz Journal of General Internal Medicine 34, 492-495, 2019 | 17 | 2019 |
| Added therapeutic benefit of top-selling brand-name drugs in Medicare AC Egilman, BN Rome, AS Kesselheim JAMA 329 (15), 1283-1289, 2023 | 14 | 2023 |
| Evaluation of trials comparing single-enantiomer drugs to their racemic precursors: A systematic review AS Long, AD Zhang, CE Meyer, AC Egilman, JS Ross, JD Wallach JAMA Network Open 4 (5), e215731-e215731, 2021 | 11 | 2021 |
| Medicare spending and potential savings on brand-name drugs with available generic substitutes excluded by 2 large pharmacy benefit managers, 2012 through 2015 AC Egilman, JD Wallach, JS Ross, SS Dhruva JAMA Internal Medicine 178 (4), 567-569, 2018 | 10 | 2018 |
| Spending by the Centers for Medicare & Medicaid Services before and after confirmation of benefit for drugs granted US Food and Drug Administration accelerated approval, 2012 … JJ Skydel, AC Egilman, JD Wallach, R Ramachandran, R Gupta, JS Ross JAMA Health Forum 3 (5), e221158-e221158, 2022 | 9 | 2022 |
| Optimizing the data available via Health Canada’s clinical information portal AC Egilman, JS Ross, M Herder CMAJ 193 (33), E1305-E1306, 2021 | 7 | 2021 |
| Confidentiality orders and public interest in drug and medical device litigation AC Egilman, AS Kesselheim, HM Krumholz, JS Ross, J Kim, A Kapczynski JAMA Internal Medicine 180 (2), 292-299, 2020 | 7 | 2020 |
| Medicare Part D spending on single-enantiomer drugs versus their racemic precursors AC Egilman, AD Zhang, JD Wallach, JS Ross Annals of internal medicine 171 (7), 521-523, 2019 | 7 | 2019 |
| Digital medicine systems: an evergreening strategy or an advance in medication management? AC Egilman, JS Ross BMJ Evidence-Based Medicine 24 (6), 203-204, 2019 | 5 | 2019 |
| Medicare spending on drugs and biologics not recommended for coverage by international health technology assessment agencies AC Egilman, JD Wallach, SS Dhruva, GS Gonsalves, JS Ross Journal of General Internal Medicine 34, 2319-2321, 2019 | 5 | 2019 |
| Using multiple authorized generics to maintain high prices: the example of entacapone BN Rome, AC Egilman, NG Patel, AS Kesselheim Value in Health 26 (3), 370-377, 2023 | 4 | 2023 |
| Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017 AC Egilman, JD Wallach, CJ Morten, P Lurie, JS Ross Research Integrity and Peer Review 4, 1-8, 2019 | 4 | 2019 |
Joseph S. RossYale UniversityVerifierad e-postadress på yale.edu
